



Screen Type 1 Diabetes early, intervene sooner.

Navigate your population studies with confidence.

When assessing insulin-producing cells across large populations, establishing reliable foundations is essential. Our complete assay – built around the globally trusted GSP™ instrument – is designed to yield publication-ready data, helping laboratories transform their research initiatives.

Fully automated autoantibody testing from dried blood spots.

Our integrated assay harnesses the power of the GSP and the convenience of dried blood spot (DBS) cards alongside our targeted autoantibody kit to simplify your science. One partner, one complete solution.



High-throughput: requires minimal manual intervention for population-scale studies, with a semi-automated DELFIA option available for lower volumes



Reliable: assay leverages our DELFIA technology for maximum precision – a proven newborn screening technology used in 110+ countries



Efficient: dried blood spot method eliminates cold chain requirements, enabling simpler collection and streamlining population-wide studies

Product under development according to CE-IVDR requirements

GSP T1D 3plex kit is under development according to CE-IVDR requirements. Please contact your local representative for information.
GSP: Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.
GSP: CE marked in vitro diagnostic medical device, compliant with IVD Regulation (EU) 2017/746

Sample accessioning and punching by Panthera or DBS puncher

- 2 x 3.2 mm punches per sample
- Prepare up to 9 microtitration plates at once (Panthera)



Sample analysis by GSP

- Fully automatic from plate loading
- **Capacity:** 12 plates x 96 samples
- **Assay protocol:** 9 hours



Semi-automated option is also available.

Results reporting in GSP workstation

- GAD/IA-2/ZnT8 combined positive/negative
- If positive, a confirmatory test for individual AAbs is required*



*Available worldwide through network of Revvity service laboratories (kit not available for purchase)

Introducing the GSP GAD/IA-2/ZnT8 AAb kit



Target critical biomarkers in insulin-producing cells with one multiplex kit. Our solution offers an efficient method for simultaneous semiquantitative detection of antibodies.

Antibodies tested:

- GAD65 (glutamic acid decarboxylase 65)
- IA-2 (islet antigen-2)
- ZnT8 (zinc transporter 8)

Advance your research in pancreatic autoimmunity.



Learn more

Scan or click for more information



Contact us

Scan or click for more information

GSP T1D 3plex kit is under development according to CE-IVDR requirements. Please contact your local representative for information.
GSP, DBS puncher and Panthera: CE marked in vitro diagnostic medical device, compliant with IVD Regulation (EU) 2017/746
GSP and DBS puncher: Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.



www.revvity.com

Copyright ©2026, Revvity, Inc. All rights reserved.
Revvity is a trademark of Revvity, Inc.

All other trademarks are the property of their respective owners.

For *in vitro* diagnostic use. This product is only available where licensed in accordance with law. Please contact your local representative for availability.

2569300